EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β‐lactamase inhibitor combination

Terese L Katzenstein iD, Daniel Faurholt-Jepsen iD, Tavs Qvist iD, Peter Østrup Jensen iD, Tacjana Pressler iD, Helle Krogh Johansen iD, Mette Kolpen iD

APMIS · 2023

DOI: 10.1111/apm.13331 ↗

At a glance

Journal article in APMIS, 2023. Written by Terese L Katzenstein and 6 co-authors. Institution: Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. Major MEDLINE topics: Cystic Fibrosis, Pseudomonas Infections. Cited 4 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Ceftolozane‐tazobactam is a new β‐lactam/β‐lactamase inhibitor combination approved by the U.S. Food and Drug Administration in 2019 for the treatment of hospital‐acquired and ventilator‐associated pneumonia. The combination is a particularly potent inhibitor of penicillin‐binding proteins with higher affinity than other β‐lactam agents. Persons with cystic fibrosis (pwCF) often harbour resistant Gram‐negative bacteria in the airways and need antibiotics to prevent declining lung function. To test whether the introduction of ceftolozane‐tazobactam in the period 2015–2020 led to a bacterial population level increase in cephalosporin resistance in a Danish CF population. In vitro , activity of ceftolozane‐tazobactam was evaluated by susceptibility testing of clinical Pseudomonas aeruginosa isolated from pwCF from January 1, 2015, to June 1, 2020. Six thousand three hundred thirty two isolates collected from 210 adult pwCF were included. Thirty pwCF were treated with ceftolozane‐tazobactam at least once. Ceftolozane‐tazobactam exposure did not increase cephalosporin resistance on an individual or population level. However, resistance to ceftolozane‐tazobactam was recorded despite no prior exposure in four pwCF. Compared to ceftazidime, ceftolozane‐tazobactam had a better in vitro activity on P. aeruginosa . The percentage of non‐mucoid P. aeruginosa isolates susceptible to ceftolozane‐tazobactam were higher or equal to 5 other β‐lactams. Ceftolozane‐tazobactam expands the armamentaria against P. aeruginosa with acceptable levels for a selection of drug resistance.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisPseudomonas InfectionsHumansAdultAnti-Bacterial Agentsbeta-Lactamase InhibitorsPseudomonas aeruginosaCephalosporinaseDrug Resistance, BacterialCephalosporinsTazobactamMonobactamsMicrobial Sensitivity TestsDrug Resistance, Multiple, Bacterial

Author keywords

Ceftolozane + tazobactamPseudomonas aeruginosacystic fibrosis

Substances

ceftolozaneAnti-Bacterial Agentsbeta-Lactamase InhibitorsCephalosporinaseCephalosporinsceftolozane, tazobactam drug combinationTazobactamMonobactams

Authors and institutions

  • Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
  • Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.
  • Cystic Fibrosis Center, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.

ORCID profiles: Terese L Katzenstein, Daniel Faurholt-Jepsen, Tavs Qvist, Peter Østrup Jensen, Tacjana Pressler, Helle Krogh Johansen, Mette Kolpen

Cite

APA

Katzenstein, T. L., Faurholt-Jepsen, D., Qvist, T., Jensen, P. Ø., Pressler, T., Johansen, H. K., & Kolpen, M. (2023). Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β‐lactamase inhibitor combination. APMIS. https://doi.org/10.1111/apm.13331

Vancouver

Katzenstein TL, Faurholt-Jepsen D, Qvist T, Jensen PØ, Pressler T, Johansen HK, et al. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β‐lactamase inhibitor combination. APMIS. 2023. doi:10.1111/apm.13331

BibTeX
@article{Katzenstein2023,
  author = {Katzenstein, Terese L and Faurholt-Jepsen, Daniel and Qvist, Tavs and Jensen, Peter Østrup and Pressler, Tacjana and Johansen, Helle Krogh and Kolpen, Mette},
  title = {Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β‐lactamase inhibitor combination},
  journal = {APMIS},
  year = {2023},
  doi = {10.1111/apm.13331}
}
Start for free →